Clinical evaluation of fluconazole in patients with mycotic infection
Matsushima, T.; Ikeda, H.; Tomizawa, S.; Nakamura, J.; Adachi, M.; Kawanishi, M.; Tanabe, J.; Tano, Y.
Japanese Journal of Antibiotics 42(1): 153-163
1989
ISSN/ISBN: 0368-2781 PMID: 2540361 Document Number: 340439
Fluconazole, a triazole antifungal agent newly developed by Pfizer Inc., was given orally to 4 patients with deep mycosis. Fluconazole was markedly effective against septicemia due to Candida and oral candidiasis accompanied with lingual ulcer in spite of seriousness of these underlying disease. In 2 patients with aspergilloma, eradication or contraction of fungus ball was observed and the drug was judged to be effective. In vitro MICs of fluconazole against clinically isolated Aspergillus ssp. were much higher than its serum levels leaving a large discrepancy between in vitro activity and clinical efficacy. Although the dosage was 100 .apprx. 300 mg daily for 8 days to 6 months, neither adverse reactions nor laboratory parameter abnormalities were observed. The above results suggest that fluconazole is a useful agent in the treatment of fungal infections.